TGA Amends Clinical Decision Support Software Exemption: Effective 1 November 2026; Artificial Intelligence and Black-Box Systems Remain Ineligible

News

TGA Amends Clinical Decision Support Software Exemption: Effective 1 November 2026; Artificial Intelligence and Black-Box Systems Remain Ineligible

Published 4 October 2026, 13:32. Category: Technical Guidance.

The Therapeutic Goods Administration (TGA) of Australia announced on 8 September 2026 that it has amended the exemption provisions for clinical decision support systems (CDSS). The new rules take effect on 1 November 2026. TGA states plainly that this amendment only writes the applicable boundaries of the exemption more clearly; it does not change the scope of the exemption or create new regulatory requirements.

Where the Exemption Applies

Under Australia's Therapeutic Goods (Medical Devices) Regulations 2002, if software falls within the definition of a medical device, it generally must be included in the Australian Register of Therapeutic Goods (ARTG) before it can be supplied. Exemptions and exclusions are exceptions. CDSS can perform a wide range of functions, from medication risk alerts to diagnostic or treatment recommendations. TGA confirms that the CDSS exemption continues to apply to a set of qualifying low-risk software.

Three Conditions Must Be Met Cumulatively

TGA guidance states that a CDSS is exempt only if it satisfies three conditions at the same time. First, the manufacturer's sole intended purpose for it is to provide or support a recommendation to a healthcare professional; it must not itself diagnose, determine treatment, override clinical judgment, or perform patient monitoring. Second, it must not directly process or analyze medical images or signals from other medical devices, including data from in vitro diagnostic devices. Retrieving and displaying information from electronic medical records may be acceptable; once data are interpreted, results are generated, or the software is used for patient monitoring, the condition is no longer met.

Transparency Is a Mandatory Threshold

The third condition focuses on explainability. The software must be able to explain how the recommendation was derived; it cannot rely on proprietary analysis or artificial intelligence to output recommendations. It must also make it easy for clinicians to verify whether the recommendation is accurate and must identify the underlying logic, clinical guidelines, processes, or evidence. TGA calls such reviewable systems 'glass box' systems, for example a computerized flowchart built on established clinical guidelines. Conversely, 'black box' systems, where only inputs and outputs can be seen and internal operation cannot be observed, do not satisfy this condition.

Artificial Intelligence Software Is Outside the Exemption

TGA guidance provides a clear conclusion: CDSS with artificial intelligence capabilities do not satisfy the exemption conditions. The guidance also states that black-box CDSS do not satisfy the third condition and therefore are not exempt. In practice, artificial intelligence software for image recognition, risk prediction, or automated recommendation of treatment pathways generally must follow the ARTG inclusion pathway rather than relying on the exemption.

Consequences of Not Qualifying

If software is a medical device but does not satisfy all three conditions, it must be included in the ARTG before it can be supplied in Australia, unless another exemption applies. Even if all three conditions are met, the software is only potentially an exempt medical device; manufacturers must still comply with regulatory obligations applicable to exempt devices. Exemption does not mean exemption from regulation.

Sources and Scope of Application

Source: Therapeutic Goods Administration (TGA) news article, 'Clinical decision support system exemption amendments', published 8 September 2026: https://www.tga.gov.au/news/news-articles/clinical-decision-support-system-exemption-amendments

TGA guidance, 'Understanding clinical decision support system software regulation': https://www.tga.gov.au/resources/guidance/understanding-clinical-decision-support-system-software-regulation

Federal Register of Legislation (Australia), 'Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026' (F2026L01167, registered 7 September 2026): https://www.legislation.gov.au/F2026L01167/asmade

Verification scope and access date: This review verified the above TGA news article and guidance page, as well as the registration information for the amending regulation in the Federal Register of Legislation; access date 4 October 2026.

Applicability note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company, or registration application. The official text prevails. Requirements may change with subsequent official updates; please refer to the latest TGA publications.

AIMEILI Regulatory Interpretation

The TGA amendment is a clarification, not a substantive expansion. It preserves the existing low-risk CDSS exemption but sharpens the compliance boundary for software with artificial intelligence and opaque decision logic. For manufacturers, the key question is not whether the software is described as 'clinical decision support' but whether it meets all three cumulative conditions. If any condition fails, the exemption is unavailable.

The third condition is likely the most challenging. TGA's 'glass box' standard requires traceable, reviewable logic and underlying clinical guidelines or evidence. Systems that rely on proprietary algorithms, adaptive models, or outputs that cannot be explained to a clinician are unlikely to qualify. The guidance's statement that artificial intelligence-enabled CDSS do not meet the exemption confirms that such products should be assessed under the ARTG inclusion pathway.

The second condition also restricts direct processing or analysis of medical images, signals, and in vitro diagnostic data. Displaying electronic medical record information may remain outside the boundary, but interpreting data or generating results crosses into regulated device functionality. Software used for patient monitoring is likewise outside the exemption.

Exempt status is not deregulation. Even qualifying low-risk CDSS remain subject to applicable regulatory obligations for exempt medical devices. Manufacturers should document the basis for relying on the exemption and maintain compliance with post-market and supply-related requirements.

Business Impact

For global manufacturers and distributors, the 1 November 2026 effective date creates a clear compliance planning milestone. Products marketed in Australia that rely on the CDSS exemption should be reassessed against the three conditions, with particular attention to intended purpose, data processing, and explainability. If the product cannot satisfy all three, ARTG inclusion should be budgeted and scheduled before supply.

For CROs and regulatory affairs teams, the amendment supports earlier gap assessments and documentation updates. Technical files should demonstrate the sole intended purpose, confirm that the software does not directly analyze medical images or signals, and evidence transparent logic and clinical basis. Where artificial intelligence or black-box elements are present, the ARTG pathway, conformity assessment, and potentially clinical evidence requirements should be planned.

Commercial teams should avoid claiming that the CDSS exemption applies broadly. Distributor agreements, website claims, and promotional materials should align with the regulatory status. A product that is non-compliant with exempt-device obligations, or that should have been ARTG-listed, may face supply interruptions, recalls, or enforcement action.

Recommended next steps: conduct a portfolio triage by 1 November 2026; map each CDSS product to the three conditions; document the regulatory basis for any exemption reliance; and for artificial intelligence or black-box systems, initiate ARTG inclusion planning, including classification, conformity assessment, and Australian sponsor arrangements.

Sources

• Therapeutic Goods Administration (TGA) — 'Clinical decision support system exemption amendments', 2026-09-08.
• Therapeutic Goods Administration (TGA) — 'Understanding clinical decision support system software regulation'.
• Federal Register of Legislation (Australia) — 'Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026' (F2026L01167), 2026-09-07.